Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,639,002
  • Shares Outstanding, K 51,900
  • Annual Sales, $ 41,000 K
  • Annual Income, $ -68,360 K
  • 36-Month Beta 3.78
  • Price/Sales 41.38
  • Price/Cash Flow N/A
  • Price/Book 3.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.78
  • Number of Estimates 5
  • High Estimate -0.57
  • Low Estimate -0.89
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.13 +1.41%
on 12/18/18
40.99 -27.93%
on 12/03/18
-7.62 (-20.51%)
since 11/16/18
3-Month
29.13 +1.41%
on 12/18/18
53.97 -45.27%
on 09/19/18
-23.64 (-44.45%)
since 09/18/18
52-Week
18.66 +58.31%
on 12/20/17
73.90 -60.03%
on 05/24/18
+9.60 (+48.14%)
since 12/18/17

Most Recent Stories

More News
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.

CRSP : 29.54 (-6.46%)
January 2019 Options Now Available For CRISPR Therapeutics (CRSP)

Investors in CRISPR Therapeutics AG saw new options begin trading today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain...

CRSP : 29.54 (-6.46%)
CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive...

CRSP : 29.54 (-6.46%)
CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.

CRSP : 29.54 (-6.46%)
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3

Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.

SPPI : 10.60 (-4.50%)
CRSP : 29.54 (-6.46%)
VRTX : 163.43 (-1.65%)
AMGN : 187.10 (-1.57%)
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

--CRISPR Therapeutics Gains Additional Rights to MaxCyte's Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology--

CRSP : 29.54 (-6.46%)
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

Is (CRSP) Outperforming Other Medical Stocks This Year?

CRSP : 29.54 (-6.46%)
CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates

CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CRSP : 29.54 (-6.46%)
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.

CRON : 11.54 (+3.68%)
CRSP : 29.54 (-6.46%)
TLRY : 76.50 (+16.10%)
FGEN : 39.50 (+1.31%)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

-Initiated Phase 1/2 Clinical Trial of CTX001 in B-thalassemia-

CRSP : 29.54 (-6.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CRSP with:

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 33.32
1st Resistance Point 31.43
Last Price 29.54
1st Support Level 28.39
2nd Support Level 27.24

See More

52-Week High 73.90
Fibonacci 61.8% 52.80
Fibonacci 50% 46.28
Fibonacci 38.2% 39.76
Last Price 29.54
52-Week Low 18.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar